Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

BMS’ Q2 results beat expectations with strong performance across core therapy areas

BMS’ Q2 results beat expectations with strong performance across core therapy areas

Sales of its oncology drugs Opdivo and Yervoy also increased on the same period last year, up by 16% and 38%, respectively. ... We delivered a strong quarter across each of our four therapeutic areas, including building momentum for our new product

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer This included approvals for not only Keytruda, but also Roche’s Tecentriq (atezolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in a number of cancer types.

FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer

FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer Keytruda (pembrolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in breast, urothelial, gastric and hepatocellular cancers.

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer Twice as many patients responded to Opdivo plus Cabometyx compared to Sutent – 55.7% and 27.1%, respectively. ... Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9% with Sutent.

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting. ... In patients with resection, the pCR rate increased further to 30.5% for those receiving the Opdivo/chemotherapy

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...